Esomeprazol-induzierter kutaner Lupus erythematodes

Abstract

Proton pump inhibitors are among the most commonly used drugs worldwide. They are considered to be largely safe and cause little side-effects. We report a 69-year-old woman who suffered from erythematous plaques 2 months after initiating therapy with esomeprazole. The diagnosis of subacute cutaneous lupus erythematosus was based on the clinical picture together with characteristic histological features of a skin biopsy specimen and the detection of anti-Ro/SSA antibodies. In particular, the temporal relationship with the onset of proton pump inhibitor therapy led to the high-level suspicion of a drug-induced pathogenesis. Strengthening the initially suspected diagnosis, the characteristic skin lesions resolved almost completely without specific therapy after discontinuation of the medication. If typical skin lesions occur in light-exposed areas in connection with the administration of PPI, the possibility of a drug-induced cutaneous lupus erythematosus should always be considered. Due to the frequent recurrence rate after renewed exposure, a new therapy with PPI should be avoided.

Proton pump inhibitors‐related subacute cutaneous lupus erythematosus: Clinical characteristics, management, and outcome

“…A total of 29 patients from 19 studies with 14 case reports [11][12][13][14][15][16][17][18][19][20][21][22][23][24] and 5 case series [25][26][27][28][29] included, and 23 of the 29 patients were female (Figure 1). The median age was 61 years (range 19-85) old, and 19 cases (65.5%) were over 60 years old (Table 1).…”